Atossa Genetics Inc. (NASDAQ:ATOS) Receives $6.25 Average PT from Brokerages

Atossa Genetics Inc. (NASDAQ:ATOS) has been given a consensus rating of “Hold” by the five analysts that are presently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $6.3333.

ATOS has been the topic of a number of analyst reports. Ascendiant Capital Markets upped their target price on Atossa Genetics from $7.75 to $8.00 and gave the company a “buy” rating in a research note on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Atossa Genetics in a research report on Wednesday, October 8th. Finally, Zacks Research lowered Atossa Genetics from a “hold” rating to a “strong sell” rating in a research note on Monday, October 13th.

Atossa Genetics Stock Down 2.2%

Shares of ATOS opened at $0.78 on Thursday. The business has a fifty day moving average of $0.88 and a 200 day moving average of $0.85. The company has a market cap of $100.96 million, a PE ratio of -3.26 and a beta of 0.95. Atossa Genetics has a 52-week low of $0.55 and a 52-week high of $1.30.

Atossa Genetics (NASDAQ:ATOS) last released its earnings results on Wednesday, November 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). As a group, research analysts anticipate that Atossa Genetics will post -0.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Atossa Genetics

Institutional investors have recently modified their holdings of the stock. Bank of America Corp DE boosted its holdings in shares of Atossa Genetics by 55.8% in the third quarter. Bank of America Corp DE now owns 155,169 shares of the company’s stock valued at $135,000 after purchasing an additional 55,568 shares during the period. Squarepoint Ops LLC raised its position in Atossa Genetics by 39.9% during the 3rd quarter. Squarepoint Ops LLC now owns 253,343 shares of the company’s stock valued at $220,000 after purchasing an additional 72,235 shares in the last quarter. GSA Capital Partners LLP lifted its holdings in shares of Atossa Genetics by 509.0% in the 3rd quarter. GSA Capital Partners LLP now owns 310,754 shares of the company’s stock worth $269,000 after buying an additional 259,725 shares during the period. Vanguard Group Inc. grew its position in shares of Atossa Genetics by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock worth $5,270,000 after buying an additional 245,717 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of Atossa Genetics by 1,294.2% during the third quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock valued at $33,000 after buying an additional 35,474 shares during the period. 12.74% of the stock is owned by hedge funds and other institutional investors.

About Atossa Genetics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.